GILD Gilead Sciences Inc

Price (delayed)

$68.16

Market cap

$85.44B

P/E Ratio

69.55

Dividend/share

$2.72

EPS

$0.98

Enterprise value

$101.84B

Sector: Healthcare
Industry: Drug Manufacturers - General

Gilead Sciences, Inc. /ˈɡɪliəd/, is an American biopharmaceutical company headquartered in Foster City, California that researches, develops and commercializes drugs. The company focuses primarily on antiviral drugs used in the ...

Highlights

The quick ratio has grown by 40% from the previous quarter and by 7% YoY
GILD's gross profit is up by 5% QoQ and by 2.7% YoY
GILD's EPS has dropped by 54% year-on-year
The company's net income has shrunk by 53% YoY

Key stats

What are the main financial stats of GILD
Market
Shares outstanding
1.25B
Market cap
$85.44B
Enterprise value
$101.84B
Valuations
Price to earnings (P/E)
69.55
Price to book (P/B)
4.9
Price to sales (P/S)
3.7
EV/EBIT
37.03
EV/EBITDA
24.52
EV/Sales
4.4
Earnings
Revenue
$23.15B
EBIT
$2.75B
EBITDA
$4.15B
Free cash flow
$8.16B
Per share
EPS
$0.98
Free cash flow per share
$6.5
Book value per share
$13.91
Revenue per share
$18.44
TBVPS
$34.92
Balance sheet
Total assets
$60.88B
Total liabilities
$43.41B
Debt
$29.29B
Equity
$17.45B
Working capital
$21.42B
Liquidity
Debt to equity
1.68
Current ratio
3.25
Quick ratio
2.93
Net debt/EBITDA
3.95
Margins
EBITDA margin
17.9%
Gross margin
79%
Net margin
5.5%
Operating margin
10.9%
Efficiency
Return on assets
2.1%
Return on equity
6.3%
Return on invested capital
5.8%
Return on capital employed
5.4%
Return on sales
11.9%
Dividend
Dividend yield
3.99%
DPS
$2.72
Payout ratio
277.6%

GILD stock price

How has the Gilead Sciences stock price performed over time
Intraday
1.82%
1 week
7.63%
1 month
19.43%
1 year
7.93%
YTD
16.99%
QTD
16.99%

Financial performance

How have Gilead Sciences's revenue and profit performed over time
Revenue
$23.15B
Gross profit
$18.29B
Operating income
$2.51B
Net income
$1.27B
Gross margin
79%
Net margin
5.5%
Gilead Sciences's net margin has shrunk by 54% YoY
The company's net income has shrunk by 53% YoY
The operating margin has contracted by 44% YoY
The operating income has declined by 42% year-on-year

Growth

What is Gilead Sciences's growth rate over time

Valuation

What is Gilead Sciences stock price valuation
P/E
69.55
P/B
4.9
P/S
3.7
EV/EBIT
37.03
EV/EBITDA
24.52
EV/Sales
4.4
GILD's EPS has dropped by 54% year-on-year
Gilead Sciences's equity has decreased by 15% YoY and by 3.2% from the previous quarter
The stock's price to book (P/B) is 9% more than its last 4 quarters average of 4.5 and 2.1% more than its 5-year quarterly average of 4.8
GILD's price to sales (P/S) is 5% less than its last 4 quarters average of 3.9
GILD's revenue is up by 4.4% since the previous quarter and by 3.5% year-on-year

Efficiency

How efficient is Gilead Sciences business performance
GILD's return on assets has dropped by 51% year-on-year
Gilead Sciences's ROIC has plunged by 50% YoY
GILD's return on sales is down by 50% year-on-year
The company's return on equity fell by 49% YoY

Dividends

What is GILD's dividend history
DPS
$2.72
Dividend yield
3.99%
Payout ratio
277.6%
Recent dividends

Financial health

How did Gilead Sciences financials performed over time
GILD's total assets is 40% higher than its total liabilities
The quick ratio has grown by 40% from the previous quarter and by 7% YoY
Gilead Sciences's current ratio has increased by 39% QoQ and by 10% YoY
Gilead Sciences's debt is 68% higher than its equity
The company's debt to equity rose by 41% YoY and by 25% QoQ
Gilead Sciences's debt has increased by 22% QoQ and by 19% YoY

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.